3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
Vincristine
13
Temozolomide
12
Cyclophosphamide
11
Irinotecan
8
Magnetic Resonance Spectroscopy
7
X-Rays
6
Vinorelbine
6
Specimen Handling
6
Phantoms, Imaging
6
Dactinomycin
6
Biopsy
5
fludarabine
4
Radiotherapy
4
Radiation
4
Nuclear Medicine Department, Hospital
4
Filgrastim
4
Etoposide
4
pegfilgrastim
3
irinotecan sucrosofate
3
Sirolimus
3
Proton Therapy
3
Melphalan
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
amino-acid, glucose, and electrolyte solution
×
1 year
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled